Objective Prolonged treatment with antiretroviral drugs results in the selection of HIV-1
variants with mutations conferring resistance to nucleoside and non-nucleoside reverse …

S-1153 (AG1549) is perhaps the most promising non-nucleoside inhibitor of HIV-1 reverse
transcriptase currently under development as a potential anti-AIDS drug, because it has a …

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) target HIV-1 reverse transcriptase
(RT) by binding to a pocket in RT that is close to, but distinct, from the DNA polymerase …

ABSTRACT A research program targeted toward the identification of expanded-spectrum
nonnucleoside reverse transcriptase inhibitors which possess increased potency toward …

Abstract Comparison of the recently solved structure of HIV-1reverse transcriptase (RT)-DNA-
dNTP ternary complex with the previously solved structure of RT-DNA binary complex …

Human immunodeficiency virus-1 reverse transcriptase (RT) inhibition is a major focus of
current anti-AIDS drug discovery and development programs, comprising 17 of the 31 Food …

Initiation of human immunodeficiency virus type 1 (HIV‐1) reverse transcription requires
specific recognition of the viral genome, tRNA 3 Lys, which acts as primer, and reverse …

Along with nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs),
nonnucleoside reverse transcriptase inhibitors (NNRTIs) have gained a definitive and …

The non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTI) are a class of
compounds that present a common butterfly-like conformation. In the present study, the …

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are allosteric inhibitors of the HIV
type 1 (HIV-1) reverse transcriptase (RT). Yeast grown in the presence of many of these …